Tevogen Bio Stock Soars on Expanded Team-Up with Microsoft

Dow Jones
01-27
 

By Dean Seal

 

Shares of Tevogen Bio surged after the company said it has broadened its relationship with Microsoft in an AI-focused collaboration to develop the biotech's proprietary technology.

The stock was up 52% at $2.06 in premarket trading on Monday. Shares were trading at $7.58 this time a year ago.

The Warren, N.J., company said after the market closed last week that Microsoft is using its AI and cloud capabilities to help build Tevogen's PredicTcell technology, which is designed for predictive precision T-cell targeting.

Microsoft's health and life sciences domain expertise should accelerate Tevogen's target identification and pre-clinical processes, the company said.

 

Write to Dean Seal at dean.seal@wsj.com

 

(END) Dow Jones Newswires

January 27, 2025 06:37 ET (11:37 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10